Why is "Casirivimab/imdevimab" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-23 13:44:14
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Casirivimab/imdevimab entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-03-23 and was most recently seen on 2026-03-23.
Wikipedia Overview
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Insights into the structural differences between homo- and heterodimers enriched from a cocktail of monoclonal antibodies against SARS-CoV-2 - Nature
-
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 - NEJM
-
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial - The Lancet
-
Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant - Springer Nature Link
-
Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV) - Cureus
-
REGEN-COV (Casirivimab with Imdevimab) for the Treatment of Mild to Moderate Covid-19 - Clinical Trials Arena
-
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies - ASM Journals
-
FDA Authorizes Use of COVID-19 Antibody Therapy for Postexposure Prophylaxis - Medical Professionals Reference
-
The WHO has advised against the use of two antibody therapies against COVID – here’s what that means - The Conversation
-
WHO 'strongly advises against' use of two COVID treatments - Reuters
-
FDA Authorizes REGEN-COV for Post-Exposure Prophylaxis for COVID-19 - idse.net
-
News - Reduced Efficacy of Ronapreve (Casirivimab/Imdevimab) against Omicron Variant - Paul-Ehrlich-Institut
-
COVID-19: FDA authorises Regeneron antibody drug given to Trump - Al Jazeera
-
Most Monoclonal Antibody Treatments Don’t Work Against Omicron—Here’s Why - Prevention
-
FDA Revokes EUAs of Four COVID-19 Monoclonal Antibodies - MedPage Today
-
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 - NEJM
-
Regen-COV Reduces Viral Load in Patients Hospitalized with COVID-19 - idse.net
-
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy - Nature
-
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 - NEJM
-
SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines - Nature
-
Warp Speed readies to distribute new drug cocktail for COVID-19 - army.mil
-
Ronapreve: new COVID-19 treatment has just been authorised – here’s everything you need to know - The Conversation
-
Regeneron: Antibody cocktail helps prevent symptomatic COVID-19 - American Hospital Association
-
Covid-19: UK approves first monoclonal antibody treatment - The BMJ
-
REGEN-COV cuts viral load within 7 days in COVID-19 patients - drugdiscoverytrends.com
-
FDA authorizes emergency use of Regeneron antibody treatment given to Trump - axios.com
-
Evidence-Based Recommendations on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies (Casirivimab + Imdevimab, and Sotrovimab) for Adults in Ontario - Institute of Health Emergencies and Pandemics
-
Call to keep antibody cocktail drug available for Covid care in AP - Deccan Chronicle
-
Evidence-Based Recommendations on the Use of Casirivimab + Imdevimab, and Sotrovimab for Adults in Ontario - Institute of Health Emergencies and Pandemics
-
FDA Expands Authorized Use of Regen-Cov as Preventative Treatment - respiratory-therapy.com
-
Japan's Chugai applies for approval of antibody treatment for COVID-19 - Reuters
-
Regeneron’s COVID-19 Antibody Cocktail Now Available for Some Patients Under EUA - BioSpace
-
Single Injection of Monoclonal Antibodies Reduces Risk of Symptomatic SARS-CoV-2 Infection - Patient Care Online
-
Regeneron drug saves lives in severe COVID-19, but it's not for all - pharmaphorum
-
Cipla to market Roche’s Covid-19 antibody cocktail in India - Pharmaceutical Technology
-
Regeneron's COVID-19 antibody cocktail gets US emergency licence - pharmaphorum
-
Feds approve Regeneron’s antibody therapy as COVID-19 preventive - McKnight's Long-Term Care News
-
More Transmissible Delta Variant Dances Around COVID Vaccines - The Wire Science
-
A man who had COVID-19 for 411 days is finally cured - Scimex
-
Regeneron’s Covid-19 antibodies help those who can’t make their own - chemistryworld.com
-
Regeneron, UPenn Gene Therapy Program Partner on COVID-19 Treatment via Nasal Spray - Inside Precision Medicine
-
Japan approves second drug for mildly ill COVID-19 patients - The Japan Times
-
Hospitals offer antibody, antiviral treatments - - dominionpost.com
-
COVID-19 treatment: Roche, Cipla launch antibody cocktail Casirivimab and Imdevimab in India, costs Rs... - Moneycontrol.com
-
Regeneron Claims Its Covid-19 Antibody Therapy Demonstrated Promise in Hospitalised Patients - NDTV Profit
-
What treatment options for Covid-19 are available in Hong Kong and do they work? - South China Morning Post
-
Clear efficacy for REGEN-COV in Phase III leads IDMC to recommend no placebo group enrollement - thepharmaletter.com
-
Coronavirus antibody therapies explained - DW.com
-
FDA authorizes REGEN-COV for post-exposure prophylaxis - EMS1
-
Regeneron clinic in Fort Pierce under capacity in opening days as COVID cases spike - tcpalm.com
-
Covid-19: Two Chennai hospitals launch antibody cocktail treatment - The Times of India
-
Antibody cocktail emerging as ray of hope but high cost of therapy still a deterrent - The Indian Express
-
Fact Check: Was Regeneron’s COVID-19 Treatment Tested on Cells Derived From Fetal Tissue? - newsweek.com
-
Swann welcomes Ronapreve for treatment of Covid-19 - health-ni.gov.uk
-
Haryana: 84-yr-old covid patient treated with antibody cocktail, discharged - The Indian Express
-
Roche’s antibody Covid drug now available in India - Telangana Today
-
Roche’s Antibody Cocktail launched in India at Rs 59,750/dose - The Indian Express
-
What are Ronapreve and PF-07321332, the two new COVID-19 treatments Australia has gained access to? - ABC News & Headlines – Australian Broadcasting Corporation
-
Covid: First Indian to get Trump cocktail discharged from hospital - rediff.com
-
COVID antibody cocktail used to treat Donald Trump now launched in India - ANI News
-
Roche reports promising results from anti-Covid cocktail - The Malaysian Reserve
-
2 Covid positive senior citizens get antibody cocktail therapy at pvt hospital in Delhi - The Times of India
-
News Details - Ministry of Health - moh.gov.bh
-
COVID antibody treatment gets wider-use approval from Japan health ministry panel - 毎日新聞
-
EMA recommends authorisation of two monoclonal antibody medicines - Philenews
-
Covid-19: Antibody cocktail treatment begins at Delhi's Sir Ganga Ram Hospital | Latest News Delhi - Hindustan Times
-
Cocktail drug cures Covid in 2-3 days, but at steep cost - newindianexpress.com
-
Antibody cocktail jab as new hope for survival of Covid patients - Deccan Chronicle
-
European Commission approves Ronapreve to treat Covid-19 - Indian Pharma Post
-
Sim: Ronapreve Covid-19 Medicine Currently Only Available In Sarawak - CodeBlue
-
Narayan Memorial Hospital Behala successfully conducts 'Antibody Cocktail Therapy' on two of its patients - IBG News
-
Roche's drug to treat Covid now available in India: Check price, who can take it - Livemint
-
India approves Roche/Regeneron drug for Covid-19 treatment - Livemint
-
Covid-19: Cocktail antibodies injection used first time in Andhra Pradesh - Livemint
-
Covid-19: Cocktail drug considerably reduces hospital stay, say doctors - Mid-Day
-
Monoclonal antibody 'successfully' used in 2 patients at Sir Ganga Ram hospital; one discharged within 12 hrs - India TV News
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.